Novo Nordisk reported Q1 sales of $15.17 billion, beating expectations, driven by strong uptake of its Wegovy weight loss pill launched in January 2026. Weekly prescriptions surpassed 200,000 by mid-April, with over 2 million total since launch, boosting quarterly sales to 2.26 billion Danish kroner. The company raised its 2026 sales guidance to $42.39-$46.24 billion, citing continued growth in GLP-1 products and international expansion plans. Shares rose 7.11% in premarket trading following the update.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
